ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 761

Polymyalgia Rheumatica: Winter Is Coming

Diane Marsman1, Aatke van der Maas 1, Alfons den Broeder 1, Frank van den Hoogen 1, Nathan den Broeder 1 and Nadine Boers 2, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Sint Maartenskliniek, Nijmegen

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: polymyalgia rheumatica and environmental factors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The cause for polymyalgia rheumatic (PMR) is currently unknown. Disease onset may be triggered by a combination of genetic predisposition and environmental factors such as infection.1 In different regions of Denmark a simultaneous peak incidence of giant cell arthritis and PMR occurred together with epidemics of Mycoplasma pneumoniae, Chlamydophila pneumoniae and Parvovirus B19.1 A seasonal epidemics pattern for PMR would be supporting evidence for an infectious cause.1 However, the current evidence of seasonal effect on the occurrence and disease severity of PMR is limited and show conflicting results.2,3 We therefore aim to evaluate whether there is a seasonal effect on the risk of developing PMR in the Netherlands.

Methods: We retrospectively collected data on patient-, disease,- and treatment characteristics from newly diagnosed PMR patients (clinical diagnosis) who visited our outpatient clinic during April 2012 and September 2017. Exclusion criteria was other concomitant inflammatory rheumatic disease. Based on the onset of PMR (start symptoms, not time of diagnosis) patients were grouped per month. Descriptive statistics were used [mean (SD), median (p25-p75) or n (%) as appropriate]. The Chi square goodness of fit test was used to determine whether the incidence of onset of symptoms was different between months of the year.

Results: In total 448 patients were included and 55 % were female and mean age was 66 years. Other baseline characteristics are described in table 1. The chi-square goodness of fit test to determine whether there was a peak incidence in months was p=0.06. As shown in figure 1 the incidence of onset PMR symptoms is higher in December-January, April through June with a peak in August. The April-June peaks coincides with incidence peaks of Mycoplasma pneumoniae infections and possibly Parvovirus B19 in spring and summer, The December-January peak coincides with Parvovirus B19 infections.4,5

Conclusion: No definitive seasonal effect was found on risk of developing PMR, although a bimodal seasonal pattern compatible with the proposed respiratory infections is suggested.

Baseline Characteristics Of PMR Patients

Onset of PMR Symptoms


Disclosure: D. Marsman, None; A. van der Maas, None; A. den Broeder, AbbVie, 9, Amgen, 8, Biogen, 9, BMS, 8, Boehringer Ingelheim, 8, Cellgene, 9, Fresenius, 8, Roche, 9; F. van den Hoogen, AbbVie, 5, Actelion, 2, Amgen, 8, Biogen, 5, BMS, 2, Boehringer Ingelheim, 5, Celgene, 5, Celltrion Healthcare, 5, 8, Corbus, 8, Eli Lily, 2, Janssen, 8, Mundipharma, 5, Novartis, 5, Pfizer, 2, Roche, 8, Sandoz, 8, Sanofi Genzyme, 5; N. den Broeder, None; N. Boers, None.

To cite this abstract in AMA style:

Marsman D, van der Maas A, den Broeder A, van den Hoogen F, den Broeder N, Boers N. Polymyalgia Rheumatica: Winter Is Coming [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/polymyalgia-rheumatica-winter-is-coming/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/polymyalgia-rheumatica-winter-is-coming/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology